KARACHI: Abbott Laboratories (Pakistan) Limited reported a notable improvement in its financial performance for the six months ended June 30, 2026, with profit after tax rising to Rs4.14 billion, compared with Rs3.54 billion recorded in the same period last year.
According to the company’s financial results submitted to the Pakistan Stock Exchange, the pharmaceutical company’s earnings increased by around 17% year-on-year, reflecting stronger sales and improved overall profitability. The financial statements are marked as unaudited.
Sales cross Rs38 billion
Abbott Laboratories recorded net sales of Rs38.03 billion during the first half of 2026, up from Rs36.41 billion in the corresponding period of 2025.
Local sales remained the primary contributor, increasing to Rs37.15 billion from Rs34.91 billion. Meanwhile, export sales declined to approximately Rs875.7 million, compared with Rs1.49 billion a year earlier.
Despite higher sales, the company’s cost of sales also increased to Rs23.58 billion from Rs23.79 billion, allowing gross profit to rise to Rs14.45 billion, compared with Rs12.61 billion in the same period last year.
Profitability strengthens
Abbott’s profit before tax and minimum tax differential stood at Rs7.04 billion for the six-month period, compared with Rs6.00 billion in the first half of 2025.
After accounting for income tax, the company posted a profit for the period of Rs4.14 billion, up from Rs3.54 billion.
The improvement was also reflected in earnings per share, which increased to Rs42.29 from Rs36.19 a year earlier.
Second-quarter performance remains positive
The company also delivered stronger results during the April-June quarter. Net sales reached Rs20.32 billion, compared with Rs19.06 billion in the same quarter last year.
Quarterly profit rose to approximately Rs2.20 billion, compared with Rs1.94 billion in the corresponding quarter of 2025. Earnings per share increased to Rs22.47 from Rs19.85.
Financial position
Abbott Laboratories’ total assets stood at approximately Rs48.76 billion as of June 30, 2026, compared with Rs46.82 billion at the end of December 2025.
The company had Rs9.44 billion in cash and cash equivalents at the end of June, compared with Rs13.34 billion at December 31, 2025. Its total equity increased to approximately Rs32.10 billion from Rs31.63 billion during the period.
The company’s cash-flow statement shows that net cash generated from operating activities stood at Rs662.38 million during the first six months, while capital expenditure on property, plant and equipment amounted to around Rs1.11 billion.
Overall, Abbott Laboratories’ first-half results point to continued growth in revenue and earnings, with higher local sales playing a key role in supporting profitability. The company said its quarterly report for the period would be transmitted through PUCARS separately within the specified time.
